Navigation Links
The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster
Date:7/20/2009

WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July 20 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and FORMA Therapeutics today announced a partnership to accelerate LLS's pipeline of research projects entering late pre-clinical development.

The collaboration will begin with a selection of ten small molecule candidates, discovered by LLS grant-funded academic researchers, deemed to have the most promise of advancing into clinical trials in the shortest period of time. FORMA will use its proprietary Computational Solvent (CS) Mapping technology to aid in structure based drug design with expert computer modeling, screening and medicinal chemistry competence to optimize and prioritize molecules that LLS and its partners may take to the clinic.

The partnership between LLS and FORMA is the latest in LLS's Therapy Acceleration Program (TAP), a bold initiative intended to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers. Through TAP, LLS is taking a results-oriented approach, partnering directly with biotechnology companies to move promising therapies more quickly along the FDA drug approval critical path.

"With its sophisticated technology suite and internal expertise to expeditiously progress the development of novel therapies, FORMA is an ideal partner to help LLS identify and optimize the most promising drug candidates and to achieve our mission of advancing life-saving blood cancer therapeutics," said John Walter LLS's chief executive officer.

"LLS has assembled a promising portfolio of innovative programs to combat a wide range of hematological cancers," says FORMA CEO Steve Tregay, Ph.D. "The team at FORMA is excited to be working with LLS on this bold initiative by providing our unique suite of drug discovery technologies to quickly translate science from the laboratory to patients in clinical trials."

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R) (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

About FORMA Therapeutics

FORMA Therapeutics is integrating transformative chemistry and biology to unlock the best targets and pathways that genomic medicine has revealed. Capitalizing on the targets and pathways validated by the Cancer Genome Atlas Project and other related efforts, FORMA is developing a new generation of cancer therapies aimed at previously elusive drug targets. The Company is achieving this by applying its proprietary cell-based screening, structure-guided drug discovery and Diversity Oriented Synthesis (DOS) technologies, which FORMA also uses to discover novel compounds for its partners in indications beyond oncology. FORMA is a global company headquartered in Cambridge, MA with additional research operations in Connecticut, Singapore and Beijing. www.formatherapeutics.com.

    Contact: LLS: Andrea Greif
            (914) 821-8958  andrea.greif@lls.org

    FORMA:   Steven Tregay, CEO
             (617) 679-1970

    FORMA Media Contact:
    MacDougall Biomedical Communications
    Douglas MacDougall or Jennifer Conrad
    (781) 235-3060


'/>"/>
SOURCE The Leukemia & Lymphoma Society (LLS)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Leukemia/Lymphoma Society Pleased to Announce Partnership in Southern Ohio with Eisen Marketing Group
2. 2009 recipient of minority scholar award begins clinical research on leukemia
3. Toronto researchers discovery points to a new treatment avenue for acute myeloid leukemia
4. New Drug Could Work Against Leukemia
5. Leukemia & Lymphoma Society Recognizes Aurora Physician as Man of the Year
6. For Kids With Leukemia, Radiation May Be Safe to Skip
7. The Leukemia & Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense
8. Taking Aim at Relapse of Leukemia in Kids
9. Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
10. Study IDs benefit of donor SCT for adults with acute myeloid leukemia
11. Donor Stem-Cell Transplant Best For Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology: